Abstract

Recent studies have suggested the feasibility of detecting H3K27M mutations in the cerebrospinal fluid of diffuse midline glioma (DMG) patients. However, cerebrospinal fluid from patients in these studies were collected mainly during biopsy, ventriculo-peritoneal shunt procedures or postmortem. We assessed circulating tumor DNA (ctDNA) extracted from cerebrospinal fluid (CSF) and plasma in a series of 12 radiographically suspected and/or pathologically confirmed diffuse midline glioma patients and assessed for H3F3A K27M mutation using digital droplet PCR. In 10 patients, CSF was obtained by lumbar puncture at presentation. A definitive detection of H3F3A K27M mutation was achieved in only one case (10%); H3F3A K27M mutation was suspected in three other cases (30%). H3F3A K27M mutation was detected in two patients in CSF obtained by ventricular tap during a ventriculo-peritoneal shunt for obstructive hydrocephalus. Cases in which a definitive assessment was possible (definite H3F3A K27M or definite H3F3A wildtype) tended to be younger (median 7.5 years vs. 40.5 years; p = 0.07) and have a higher concentration of CSF protein (median 123 mg/dL vs. 27.5 mg/dL; p = 0.21) compared to nondefinite cases. Low proliferation and apoptotic rates seemed to be characteristics of DMG unfavorable for liquid biopsy. More advanced lesions with necrosis and evidence of dissemination were unlikely to be candidates for lumbar puncture due to the fear of exacerbating obstructive hydrocephalus. Methods to safely sample CSF and a more sensitive detection of ctDNA are necessary for reliable liquid biopsy of DMG at presentation.

Highlights

  • Recurrent HIST1H3B (H3.1K27M) or H3F3A (H3.3K27M) have been reported in 50 to 80% of diffuse intrinsic pontine gliomas and thalamic gliomas [1,2,3,4,5,6]; the entity “diffuse midline gliomas, H3K27M-mutant” has been introduced in the revised fourth edition of World Health Organization Classification Tumours of the Central Nervous System (WHO2016) [7]

  • We have previously reported a 100% match of the MYD88 mutation status in circulating tumor DNA extracted from cerebrospinal fluid (CSF) and biopsied tissue in 21 primary and secondary central nervous system lymphoma patients using droplet digital PCR [8]

  • We shed light on the prospects of liquid biopsy of diffuse midline glioma (DMG) at presentation and discuss what characteristics of brain tumors make the reliable detection of circulating tumor DNA (ctDNA) in CSF possible

Read more

Summary

Introduction

Recurrent HIST1H3B (H3.1K27M) or H3F3A (H3.3K27M) have been reported in 50 to 80% of diffuse intrinsic pontine gliomas and thalamic gliomas [1,2,3,4,5,6]; the entity “diffuse midline gliomas, H3K27M-mutant” has been introduced in the revised fourth edition of World Health Organization Classification Tumours of the Central Nervous System (WHO2016) [7] The discovery of these diagnostic, genetic abnormalities has led to excitement about noninvasive diagnosis by liquid biopsy of diffuse midline gliomas (DMGs), in which radical resection is often not possible due to localization to the brainstem and thalamus. We shed light on the prospects of liquid biopsy of DMG at presentation and discuss what characteristics of brain tumors make the reliable detection of ctDNA in CSF possible

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call